Efficacy of recombinant adenoviral human p53 gene in the treatment of lung cancer‑mediated pleural effusion

Li,Kun‑Lin; Kang,Jun; Zhang,Peng; Li,Li; Wang,Yu‑Bo; Chen,Heng‑Yi; He,Yong

doi:10.3892/ol.2015.3054

May-2015 Volume 9 Issue 5

Full Size Image

Journals

International Journal of Molecular Medicine

International Journal of Molecular Medicine is an international journal devoted to molecular mechanisms of human disease.

International Journal of Oncology

International Journal of Oncology is an international journal devoted to oncology research and cancer treatment.

Molecular Medicine Reports

Covers molecular medicine topics such as pharmacology, pathology, genetics, neuroscience, infectious diseases, molecular cardiology, and molecular surgery.

Oncology Reports

Oncology Reports is an international journal devoted to fundamental and applied research in Oncology.

Experimental and Therapeutic Medicine

Experimental and Therapeutic Medicine is an international journal devoted to laboratory and clinical medicine.

Oncology Letters

Oncology Letters is an international journal devoted to Experimental and Clinical Oncology.

Biomedical Reports

Explores a wide range of biological and medical fields, including pharmacology, genetics, microbiology, neuroscience, and molecular cardiology.

Molecular and Clinical Oncology

International journal addressing all aspects of oncology research, from tumorigenesis and oncogenes to chemotherapy and metastasis.

World Academy of Sciences Journal

Multidisciplinary open-access journal spanning biochemistry, genetics, neuroscience, environmental health, and synthetic biology.

International Journal of Functional Nutrition

Open-access journal combining biochemistry, pharmacology, immunology, and genetics to advance health through functional nutrition.

International Journal of Epigenetics

Publishes open-access research on using epigenetics to advance understanding and treatment of human disease.

Medicine International

An International Open Access Journal Devoted to General Medicine.

May-2015 Volume 9 Issue 5

Full Size Image

Article

Efficacy of recombinant adenoviral human p53 gene in the treatment of lung cancer‑mediated pleural effusion

Authors:
- Kun‑Lin Li
- Jun Kang
- Peng Zhang
- Li Li
- Yu‑Bo Wang
- Heng‑Yi Chen
- Yong He
View Affiliations / Copyright

Affiliations: Department of Respiration, Daping Hospital, Third Military Medical University, Yuzhong, Chongqing 400042, P.R. China, College of Interpreting and Translation, Sichuan International Studies University, Shapingba, Chongqing 400031, P.R. China
Pages: 2193-2198
|
Published online on: March 18, 2015

https://doi.org/10.3892/ol.2015.3054
Expand metrics +

Abstract

Pleural effusion induced by lung cancer exerts a negative impact on quality of life and prognosis. The aim of the present study was to evaluate the value of the recombinant adenoviral human p53 gene (rAd‑p53) in the local treatment of lung cancer and its synergistic effect with chemotherapy. The present study retrospectively recruited 210 patients with lung cancer‑mediated pleural effusion who had adopted a treatment strategy of platinum chemotherapy. Pleurodesis was performed via the injection of cisplatin or rAd‑p53. Long‑term follow‑up was conducted to investigate the therapeutic effects of cisplatin and rAd‑p53 administration on pleural effusion and other relevant clinical indicators. The short‑term effect of pleurodesis was as follows: The efficacy rate of rAd‑p53 therapy was significantly higher compared with cisplatin therapy (71.26 vs. 54.47%), and the efficacy of treatment with ≥2x1012 viral particles of rAd‑p53 for pleurodesis was significantly greater than treatment with 40 mg cisplatin (P<0.05). Furthermore, efficacy analysis performed 6 and 12 months after pleurodesis indicated that the efficacy rate of rAd‑p53 was significantly greater than that of cisplatin (P<0.05). A comparison of median progression‑free survival (PFS) time identified a significant difference (P<0.05) between rAd‑p53 and cisplatin therapy (3.3 vs. 2.7 months); however, a comparison of median overall survival time identified no significant difference (P>0.05) between rAd‑p53 and cisplatin therapy (9.6 vs. 8.7 months). In addition, Cox regression analysis indicated that PFS was not affected by clinical indicators such as age, gender, prognostic staging and smoking status; however, PFS was affected by pathological subtype (adenocarcinoma or squamous carcinoma) in the rAd‑p53 group. rAd‑p53 administration for pleurodesis exerts long‑term therapeutic effects on the local treatment of lung cancer. Thus, a combination of rAd‑p53 and chemotherapy may exert a synergistic effect and reverse multidrug resistance.

View Figures

View References

1	Roberts ME, Neville E, Berrisford RG, Antunes G and Ali NJ: BTS Pleural Disease Guideline Group: Management of a malignant pleural effusion: British Thoracic Society pleural disease guideline 2010. Thorax. 65:(Suppl 2). ii32–ii40. 2010. View Article : Google Scholar : PubMed/NCBI
2	Bonnefoi H and Smith IE: How should cancer presenting as a malignant pleural effusion be managed? Br J Cancer. 74:832–835. 1996. View Article : Google Scholar : PubMed/NCBI
3	Kolschmann S, Ballin A and Gillissen A: Clinical efficacy and safety of thoracoscopic talc pleurodesis in malignant pleural effusions. Chest. 128:1431–1435. 2005. View Article : Google Scholar : PubMed/NCBI
4	Zhao WZ, Wang JK, Li W and Zhang XL: Clinical research on recombinant human Ad-p53 injection combined with cisplatin in treatment of malignant pleural effusion induced by lung cancer. Ai Zheng. 28:1324–1327. 2009.[(In Chinese)]. PubMed/NCBI
5	Du N, Li X, Li F, et al: Intrapleural combination therapy with bevacizumab and cisplatin for non-small cell lung cancer-mediated malignant pleural effusion. Oncol Rep. 29:2332–2340. 2013.PubMed/NCBI
6	Liu BW and Chen JJ: Tumor associated geneMedical Molecular Biology. 1st. Chinese Academy of Medical Sciences and Peking Union Medical College Press; Beijing: pp. 490–494. 2000, [(In Chinese)].
7	Achison M and Hupp TR: Hypoxia attenuates the p53 response to celluar damage. Oncogene. 22:3431–3440. 2003. View Article : Google Scholar : PubMed/NCBI
8	Frank DK: Gene therapy for head and neck cancer. Surg Oncol Clin N Am. 11:589–606. vi–vii. 2002. View Article : Google Scholar : PubMed/NCBI
9	Hofseth LJ, Hussain SP and Harris CC: p53: 25 years after its discovery. Trends Pharmacol Sci. 25:177–181. 2004. View Article : Google Scholar : PubMed/NCBI
10	Bálint EE and Vousden KH: Activation and activities of the p53 tumor suppressor protein. J Br Cancer. 85:1813–1823. 2001. View Article : Google Scholar
11	Frank DK: Intrgen advexin therapy halts tumor growth in advanced esophageal cancer patients. J News Release. 6:2–8. 2003.
12	Swisher SG and Roth JA: Clinical update of Ad-p53 gene therapy for lung cancer. Surg Oncol Clin N Am. 11:521–535. 2002. View Article : Google Scholar : PubMed/NCBI
13	Roth JA and Grammer SF: Gene replacement therapy for non-small-cell lung cancer: a review. Hematol Oncol Clin North Am. 18:215–229. 2004. View Article : Google Scholar : PubMed/NCBI
14	Dong M, Li X, Hong LJ, et al: Advanced malignant pleural or peritoneal effusion in patients treated with recombinant adenovirus p53 injection plus cisplatin. J Int Med Res. 36:1273–1278. 2008. View Article : Google Scholar : PubMed/NCBI
15	Zhang X, Hu Y, Wang J, et al: Efficacy of recombinant adenoviral human p53 gene in treatment of malignant pleural or peritoneal effusions background. Zhongguo Fei Ai Za Zhi. 16:153–156. 2013.[(In Chinese)]. PubMed/NCBI
16	Oken MM, Creech RH, Tormey DC, Horton J, Davis TE, McFadden ET and Carbone PP: Toxicity and response criteria of the Eastern Cooperative Oncology Group. Am J Clin Oncol. 5:649–655. 1982. View Article : Google Scholar : PubMed/NCBI
17	Zhang Y, Zhang Q, Zeng SX, Hao Q and Lu H: Inauhzin sensitizes p53-dependent cytotoxicity and tumor suppression of chemotherapeutic agents. Neoplasia. 15:523–534. 2013. View Article : Google Scholar : PubMed/NCBI
18	Nemunaitis J, Swisher SG, Timmons T, Connors D, et al: Adenovirus-mediated p53 gene transfer in sequence with cisplatin to tumors of patients with non-small-cell lung cancer. J Clin Oncol. 18:609–622. 2000.PubMed/NCBI
19	Swisher SG, Roth JA, Komaki R, et al: Induction of p53-regulated genes and tumor regression in lung cancer patients after intratumoral delivery of adenoviral p53 (INGN 201) and radiation therapy. Clin Cancer Res. 9:93–101. 2003.PubMed/NCBI
20	Weng Z, Qin TL, Tan SY, Liu JL, Sui J and Zhu ZB: Clinical trial for the treatment of advanced lung cancer by intratumoral injection of rAd p53. Shenzhen Zhong Xi Yi Jie He Za Zhi. 14:206–210. 2004.[(In Chinese)].
21	Guan YS, Sun L, Zhou XP, Li X, He Q and Liu Y: Combination therapy with recombinant adenovirus-p53 injection (rAd-p53) via transcatheter hepatic arterial chemoembolization for advanced hepatic carcinoma. World Chin J Digestology. 13:125–127. 2005.[(In Chinese)].
22	Peng Z: Current status of gendicine in China: recombinant human Ad-p53 agent for treatment of cancers. Human Gene Ther. 16:1016–1027. 2005. View Article : Google Scholar
23	Li M, Brooks CL, Wu-Baer F, Chen D, Baer R and Gu W: Mono- versus polyubiquitination: differential control of p53 fate by Mdm2. Science. 302:1972–1975. 2003. View Article : Google Scholar : PubMed/NCBI

Journals

International Journal of Molecular Medicine

International Journal of Oncology

Molecular Medicine Reports

Oncology Reports

Experimental and Therapeutic Medicine

Oncology Letters

Biomedical Reports

Molecular and Clinical Oncology

World Academy of Sciences Journal

International Journal of Functional Nutrition

International Journal of Epigenetics

Medicine International

Efficacy of recombinant adenoviral human p53 gene in the treatment of lung cancer‑mediated pleural effusion

This article is mentioned in:

Abstract

Related Articles